Overview

Efficacy and Safety of Degarelix One Month Dosing Regimen in Korean Patients With Prostate Cancer

Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-centre single arm trial to investigate efficacy and safety of degarelix in Korean patients with prostate cancer for bridging between CS21 trial (NCT00295750) results.
Phase:
Phase 3
Details
Lead Sponsor:
Ferring Pharmaceuticals
Collaborator:
Ferring Pharmaceuticals Korea, Ltd.